UA114601C2 - Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі - Google Patents

Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі

Info

Publication number
UA114601C2
UA114601C2 UAA201314292A UAA201314292A UA114601C2 UA 114601 C2 UA114601 C2 UA 114601C2 UA A201314292 A UAA201314292 A UA A201314292A UA A201314292 A UAA201314292 A UA A201314292A UA 114601 C2 UA114601 C2 UA 114601C2
Authority
UA
Ukraine
Prior art keywords
rivaroxaban
preparation
intermediates formed
relates
intermediates
Prior art date
Application number
UAA201314292A
Other languages
English (en)
Inventor
Єва Шіпош
Лакс Дьйордь Кованьіне
Балаж Хаваші
Балаж Вольк
Дьйордь Краснаі
Дьйордь Ружіч
Йожеф Баркоці
Лауріц Маріа Тотне
Дьюла Лукач
Андраш Боза
Ласло Йожеф Хегедюш
Тот Маріа Юліа Таборіне
Єва Печі
Original Assignee
Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU1100239A external-priority patent/HU230984B1/hu
Priority claimed from HU1100238A external-priority patent/HU230961B1/hu
Priority claimed from HU1100240A external-priority patent/HU230985B1/hu
Application filed by Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг filed Critical Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Publication of UA114601C2 publication Critical patent/UA114601C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Винахід стосується способу одержання 5-хлор-N-({(5S)-2-оксо-3-[4-(3-оксоморфолін-4-іл)-феніл]-1,3-оксазолідин-5-іл}-метил)-тіофен-2-карбоксаміду, що включає міжнародну непатентовану назву ривароксабан. Винахід стосується проміжних сполук, що одержані за даним способом.
UAA201314292A 2011-05-06 2012-05-04 Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі UA114601C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU1100239A HU230984B1 (hu) 2011-05-06 2011-05-06 Új eljárás gyógyszerhatóanyag előállítására és az eljárás során keletkező intermedierek
HU1100238A HU230961B1 (hu) 2011-05-06 2011-05-06 Új eljárás gyógyszerhatóanyag előállítására és az eljárás során keletkező intermedierek
HU1100240A HU230985B1 (hu) 2011-05-06 2011-05-06 Új kapcsolási eljárás gyógyszerhatóanyag előállítására
PCT/HU2012/000033 WO2012153155A1 (en) 2011-05-06 2012-05-04 Process for the preparation of a rivaroxaban and intermediates formed in said process

Publications (1)

Publication Number Publication Date
UA114601C2 true UA114601C2 (uk) 2017-07-10

Family

ID=89990276

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201314292A UA114601C2 (uk) 2011-05-06 2012-05-04 Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі

Country Status (8)

Country Link
US (1) US9556163B2 (uk)
EP (1) EP2705028B1 (uk)
JP (1) JP6325978B2 (uk)
EA (1) EA024685B1 (uk)
GE (1) GEP20156397B (uk)
MD (1) MD4557C1 (uk)
UA (1) UA114601C2 (uk)
WO (1) WO2012153155A1 (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011300365A1 (en) * 2010-09-07 2013-05-02 Symed Labs Limited Processes for the preparation of 4-{4-[5(S)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl} morpholin-3-one
WO2013152168A1 (en) * 2012-04-06 2013-10-10 Indiana University Research And Technology Corporation Processes for preparing rivaroxaban
EP2935255B1 (en) 2012-12-21 2017-08-16 Farma GRS, d.o.o. A process for preparation of rivaroxaban
RU2015112195A (ru) 2012-12-26 2017-01-31 Уэнбери Лтд. Альдегидное производное замещенных оксазолидинонов
PT2895176T (pt) 2012-12-26 2017-01-27 Wanbury Ltd Intermediário de rivaroxabano e a sua preparação
CN103360380B (zh) * 2013-03-13 2016-01-20 浙江天宇药业股份有限公司 一种利伐沙班的合成方法和利伐沙班的中间体及其制备
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
EP3186246A1 (en) * 2014-08-25 2017-07-05 Cipla Limited Process for the preparation of rivaroxaban
CN104311545B (zh) * 2014-09-29 2017-03-22 哈药集团制药总厂 一种利伐沙班关键中间体的制备方法
KR101811123B1 (ko) 2016-02-19 2017-12-20 일동제약(주) 신규의 모르폴린 이인산염 및 이를 이용한 고순도 리바록사반의 제조방법
RS65238B1 (sr) * 2019-12-10 2024-03-29 Lilly Co Eli Proces i međuproizvod za izradu oksetan-2-ilmetanamina

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3408327A1 (de) 1984-03-07 1985-09-12 Ludwig Heumann & Co GmbH, 8500 Nürnberg Diaminderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69912264T2 (de) * 1998-04-14 2004-07-22 Samsung Fine Chemicals Co., Ltd. Verfahren zur herstellung chiraler (s)-2,3-disubstituierter 1-propylamin-derivate
AU764980B2 (en) * 1998-11-27 2003-09-04 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1328509B1 (en) 2000-10-17 2006-03-22 Pharmacia & Upjohn Company LLC Methods of producing oxazolidinone compounds
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
JP2003206282A (ja) * 2002-01-07 2003-07-22 Daiso Co Ltd オキサゾリジン−２−オン誘導体の製造法
WO2004002973A1 (ja) * 2002-06-28 2004-01-08 Kaneka Corporation 光学活性１−置換アミノー２，３−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
WO2005006845A2 (en) 2003-07-14 2005-01-27 Agrinomics Llc Generation of plants with altered oil content
JP2007505050A (ja) 2003-09-12 2007-03-08 アルピダ エー／エス ペプチドデホルミラーゼ阻害剤としてのイソキサゾール類
DE10342570A1 (de) 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
WO2006063219A2 (en) 2004-12-09 2006-06-15 Pro-Health, Inc. Product and method for oral administration of nutraceuticals
EP1985620A4 (en) * 2006-02-07 2012-08-15 Taisho Pharmaceutical Co Ltd COMPOUND 10a-AZALIDE
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
KR100898361B1 (ko) * 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
CN101774978B (zh) * 2009-01-13 2011-09-21 联化科技股份有限公司 一种利奈唑胺的制备方法及其中间体
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
PL2459555T3 (pl) 2009-07-31 2022-03-28 Krka, D.D., Novo Mesto Sposoby krystalizacji rywaroksabanu
EP2388260A1 (de) * 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN102311400A (zh) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
US20130253187A1 (en) 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
WO2013053739A1 (en) * 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
CN102408420B (zh) * 2011-10-19 2014-10-22 汕头经济特区鮀滨制药厂 一种利伐沙班及其中间体的制备方法以及中间体化合物
CZ2012111A3 (cs) * 2012-02-16 2013-08-28 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu
CN103288814B (zh) * 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法

Also Published As

Publication number Publication date
MD4557C1 (ro) 2018-10-31
JP2014513115A (ja) 2014-05-29
MD20130094A2 (en) 2014-04-30
JP6325978B2 (ja) 2018-05-16
MD4557B1 (ro) 2018-03-31
EA201391647A1 (ru) 2014-02-28
EA024685B1 (ru) 2016-10-31
EP2705028B1 (en) 2019-08-21
US20140142303A1 (en) 2014-05-22
US9556163B2 (en) 2017-01-31
EP2705028A1 (en) 2014-03-12
GEP20156397B (en) 2015-11-10
WO2012153155A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
UA114601C2 (uk) Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі
JOP20210065A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
WO2013121436A3 (en) A process for preparation of rivaroxaban and intermediates thereof
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
MX2013007567A (es) Procedimiento para preparar poliestereteroles.
EA201500734A1 (ru) Способы получения макроциклических депсипептидов и новых промежуточных соединений
SG10201505619QA (en) Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)­benzofuran-2-ylcarbonylamino]ethoxy}benzamide
MY169028A (en) Process for making hydroxylated cyclopentylpyrimidine compounds
WO2011157390A3 (en) Process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
MX2014014138A (es) Procedimiento nuevo para la preparacion de acido 2-ciclopentil-6-metoxi-isonicotinico.
WO2012147098A3 (en) Novel process for preparation of 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) benzamide
WO2014087208A3 (en) A process of preparing alcaftadine
MX2016012485A (es) Proceso para preparar 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h -imidazo[4,5-b]piridin-2-il)piridin-2-amina.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
WO2014064712A3 (en) An improved process for the preparation of fulvestrant
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
CL2013001882A1 (es) Procedimiento de sintesis industrial del compuesto de formula (i) agomelatina, a partir de cianuro de alilo; compuestos intermediarios.
MD4477C1 (ro) Procedeu de sinteză a 3-(2-bromo-4,5-dimetoxifenil)propannitrilului şi aplicarea acestuia în sinteza ivabradinei şi a sărurilor sale de adiţie cu un acid farmaceutic acceptabil
WO2014102820A3 (en) Rivaroxaban intermediate and preparation thereof
MX2014002274A (es) Procedimiento para preparar [3-[(6-cloro-3-piridinil)metil]-2-tiaz olidiniliden]cianamida.
MY161361A (en) Substituted phenyl compounds
UY35068A (es) Nuevo procedimiento de síntesis del 3-(2-bromo-4,5-dimetoxifenil)propanonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable